NCT01559363View on ClinicalTrials.gov

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

October 11, 2012

Primary Completion Date

February 8, 2019

Study Completion Date

February 8, 2019

Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
DRUG

Tesevatinib

Pharmaceutical form: Tablets Route of administration: Oral

Trial Locations (11)

10016

New York University School of Medicine, New York

22908

University of Virginia - Nephrology Clinical Research Center, Charlottesville

44195

Cleveland Clinic, Cleveland

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

78215

Clinical Advancement Center, PLLC, San Antonio

80045

University of Colorado Denver, Denver

90025

UCLA Medical Center, Los Angeles

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Kadmon, a Sanofi Company

INDUSTRY

NCT01559363 - A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter | Biotech Hunter